CEACAM5-Targeted Immuno-PET in Androgen Receptor-Negative Prostate Cancer
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Diagnosing androgen receptor-negative prostate cancer is challenging. New immuno-PET imaging targeting CEACAM5 shows promise for detecting this aggressive cancer form.
Area Of Science
- Oncology
- Radiochemistry
- Molecular Imaging
Background
- Androgen receptor-negative (AR-) prostate cancer, including neuroendocrine prostate cancer (NEPC), is increasing.
- Diagnosis is difficult due to a lack of typical prostate cancer markers.
- CEACAM5 is a newly identified surface antigen upregulated in NEPC.
Purpose Of The Study
- To develop and evaluate an immuno-PET agent targeting CEACAM5 for delineating AR- prostate cancer in vivo.
- To assess the diagnostic potential of CEACAM5-targeting immuno-PET for AR- prostate cancer.
Main Methods
- CEACAM5 expression was analyzed in prostate cancer cell lines.
- The CEACAM5-targeting antibody labetuzumab was radiolabeled with 89Zr.
- In vivo PET imaging and ex vivo biodistribution were performed in xenograft models.
Main Results
- The NEPC cell line H660 showed strong CEACAM5 expression.
- [89Zr]Zr-DFO-labetuzumab successfully delineated NEPC (H660) and AR- DU145 xenografts.
- AR-positive LNCaP xenografts were not detected.
Conclusions
- Immuno-PET imaging with [89Zr]Zr-DFO-labetuzumab is a promising tool for diagnosing AR- prostate cancer.
- This method offers potential for improved detection of aggressive prostate cancer subtypes.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
